Quantum Stocks Near Q3 Finish Line: How IONQ, RGTI & QBTS Are Faring

Quantum pure plays remain under pressure despite meaningful commercialization and policy developments: IonQ, D-Wave and Rigetti have fallen 17.3%, 28.5% and 14.4%, respectively, during Q3. IonQ lifted its 2026 revenue outlook to $450-$460 million after acquiring SkyWater and secured a planned 2027 Superion 256 installation at NVIDIA, while D-Wave reported $35.5 million of first-half bookings, up 1,120% year over year. Rigetti and D-Wave each received up to $100 million in CHIPS R&D awards, but elevated rates, including a 3.75%-4.0% Fed target range, and persistent operating losses leave investors focused on revenue conversion and commercialization timing.

Analysis

The investable distinction is not quantum exposure but funding durability and the path from subsidized R&D to recurring commercial revenue. IONQ's vertical integration via SKYT is strategically valuable only if it improves delivery cadence, yield, or cost of ownership; otherwise the acquired semiconductor revenue can obscure the underlying quantum growth rate and dilute the scarcity multiple. QBTS has the clearest near-term conversion test: bookings must become revenue and cash collections within 1-3 quarters, while RGTI's stronger liquidity extends runway but also lowers urgency for management to constrain operating losses.

Federal awards reduce technology-development cash burn but should not be valued dollar-for-dollar as enterprise value: milestone timing, allowable-cost restrictions, matching requirements, and reimbursement mechanics can leave near-term free cash flow unchanged. The larger second-order beneficiary is SKYT, whose specialized fabrication and packaging capabilities could gain customer qualification value if quantum programs migrate from laboratory systems toward repeatable manufacturing. NVDA's involvement is primarily ecosystem validation rather than a material revenue driver; investors should not extrapolate it into near-term GPU demand.

Consensus appears too focused on rate sensitivity and too little on financing asymmetry. Well-capitalized QNT can outspend smaller public peers through a prolonged commercialization cycle, potentially making pure-play equity upside increasingly dependent on acquisitions or government programs rather than organic unit economics over 6-18 months. Conversely, a credible production deployment or revenue conversion would force a sharp rerating because current valuations largely discount technological optionality rather than measurable customer retention.

The thesis fails if Q3/Q4 results show deferred bookings, weakening backlog, rising cash burn without funded milestones, or guidance that relies disproportionately on acquired revenue. A sustained decline in long-duration yields would mechanically support the group, but should be sold into absent evidence of gross-margin expansion and repeatable customer deployments.

Key Decisions for Investors

• Maintain a 1-3 month relative-value long QBTS / short RGTI position, sized small given high beta: QBTS has the more immediate bookings-to-revenue catalyst, while RGTI needs customer activity to validate a cost-intensive deployment buildout. Exit if QBTS fails to show sequential revenue/backlog conversion or if RGTI discloses a material commercial contract.
• Do not chase IONQ on NVDA-related headlines. Establish only after earnings disclosure separates acquired SKYT revenue, quantum revenue, and pro forma gross margin; buy a post-results pullback if quantum bookings and cash burn improve simultaneously. Stop on a guidance reduction or evidence that the revenue outlook is predominantly acquired business.
• Watch SKYT as the less crowded quantum-manufacturing expression over 6-18 months. Initiate only if management identifies incremental quantum-related wafer/packaging demand or capacity utilization improvement; absent such disclosure, the connection is narrative rather than earnings-relevant.
• Use QNT's post-IPO trading and subsequent filings as the sector valuation anchor rather than treating all public quantum names as comparable. A material QNT premium with superior cash runway would support shorts in cash-burning peers; a discount despite stronger liquidity would signal broad quantum-risk appetite deterioration.
• Keep aggregate quantum exposure hedged and modest until the next reporting cycle. Reduce gross if 10-year real yields rise materially or if any company reports a cash runway below 18 months without contracted funding, as dilution risk can overwhelm technology milestones.